NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.88 USD | +98.66% |
|
+80.12% | +85.00% |
| 12:17am | Wall Street closes up ahead of inflation data | RE |
| May. 10 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 801M | Sales 2025 * | 1.06B | Capitalization | 1.24B |
|---|---|---|---|---|---|
| Net income 2024 * | -108M | Net income 2025 * | -35M | EV / Sales 2024 * | 0.5 x |
| Net cash position 2024 * | 837M | Net cash position 2025 * | 704M | EV / Sales 2025 * | 0.5 x |
| P/E ratio 2024 * |
-12.1
x | P/E ratio 2025 * |
44.8
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | +0.62% | ||
| 1 week | +80.12% | ||
| Current month | +105.08% | ||
| 1 month | +108.45% | ||
| 3 months | +120.35% | ||
| 6 months | +42.31% | ||
| Current year | +85.00% |
1 week
4.43
11.00
1 month
3.8111.00
Current year
3.5311.00
1 year
3.5311.00
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 0 M€ | +7.69% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 8.88 | +98.66% | 170,871,994 |
| 24-05-09 | 4.47 | 0.00% | 4,533,199 |
| 24-05-08 | 4.47 | -3.04% | 3,080,374 |
| 24-05-07 | 4.61 | -3.15% | 5,271,344 |
| 24-05-06 | 4.76 | -3.45% | 4,846,191 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.88
USD
Average target price
15.4
USD
Spread / Average Target
+73.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +85.00% | 1.24B | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- NVAX Stock